Enhancing patients’ access to high-quality and affordable medicinal products across the European Union while preserving the financial sustainability of healthcare systems should be the overarching aim of the current revision of the general pharmaceutical legislation.

AIM is proud to have joined forces with AIDES, Consilium Scientific, CPME, EAHP, EATG, ECL, EPHA, GHA, HOPE, NoGracias, PGEU, Pharmaceutical Accountability Foundation, Prescrire, Salud por Derecho and Wemos to outline how the revision of the general pharmaceutical legislation should:

1. Foster affordability to improve access to high-quality medicinal products,
2. Improve the assessment and evidence requirement of medicinal products’ effectiveness and safety, and
3. Ensure a sufficient supply of medicinal products and combat shortages.

The signatory organisations call on the European Commission to include the considerations that have been put forward in this joint statement in the revision of the general pharmaceutical legislation.

The joint statement is available here.